ABSTRACT
Objective To create case definitions for confirmed COVID diagnoses, COVID vaccination status, and three separate definitions of high risk of severe COVID, as well as to assess whether the implementation of these definitions in a cohort reflected the sociodemographic and clinical characteristics of COVID epidemiology in England.
Design Retrospective cohort study
Setting Electronic healthcare records from primary care (Clinical Practice Research Datalink, or CPRD) linked to secondary care data (Hospital Episode Statistics, or HES) data covering 24% of the population in England
Participants 2,271,072 persons aged 1 year and older diagnosed with COVID in CPRD Aurum between August 1, 2020 through January 31, 2022.
Main Outcome Measures Age, sex, and regional distribution of COVID cases and COVID vaccine doses received prior to diagnosis were assessed separately for the cohorts of cases identified in primary care and those hospitalized for COVID (primary diagnosis code of ICD-10 U07.1 “COVID-19”). Smoking status, body mass index and Charlson Comorbidity Index were compared for the two cohorts, as well as for three separate definitions of high risk of severe disease used in the United Kingdom (NHS Highest Risk, PANORAMIC trial eligibility, UK Health Security Agency Clinical Risk prioritization for vaccination).
Results Compared to national estimates, CPRD case estimates underrepresented older adults in both the primary care (age 65-84: 6% in CPRD vs 9% nationally) and hospitalized (31% vs 40%) cohorts, and overrepresented people living in regions with the highest median wealth areas of England (20% primary care and 20% hospital admitted cases in South East, vs 15% nationally). The majority of non-hospitalized cases and all hospitalized cases had not completed primary series vaccination. In primary care, persons meeting high risk definitions were older, more often smokers, overweight or obese, and had higher Charlson Comorbidity Index score.
Conclusions CPRD primary care data is a robust real-world data source and can be used for some COVID research questions, however limitations of the data availability should be carefully considered. Included in this publication are supplemental files for atotal of over 28,000 codes to define each of three definitions of high risk of severe disease.
What is already known on this topic?
The UK Government publishes data on cases, hospital admissions and vaccinations related to COVID in England.
There are at least three definitions of persons at high-risk of severe COVID in use in England.
What this study adds
Our study created case definitions for COVID diagnoses, COVID vaccination, and three separate definitions of high risk of severe COVID for use in the Clinical Practice Research Datalink (CPRD), a database covering 24% of England.
The COVID population in the CPRD has a different age and regional distribution than national case reports, which future studies may need to consider.
Competing Interest Statement
Dr Andersen, Dr McGrath, Ms Reimbaeva, Dr Mendes, Dr Nguyen, Dr Tsang, Ms Malhotra and Dr Yang are employees of Pfizer Inc or Pfizer Ltd and may hold Pfizer stock or stock options. Dr Rai and Mr Tritton are employees of Adelphi Real World which has received consulting fees from Pfizer Inc.
Funding Statement
This study was funded by Pfizer Inc. Employees of Pfizer, as well as employees of Adelphi Real World which has received consulting fees from Pfizer, were involved in the study design (collection, analysis, and interpretation of the data), writing of the report, and in the decision to submit the article for publication. All authors had full access to all statistical reports and tables in the study and take responsibility for the integrity of the data and accuracy of the data analysis. All results presented in all tables were quality control verified by a non-Pfizer non-Adelphi employee.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of United Kingdom's Health Research Authority gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Electronic health records are considered sensitive data in the UK by the Data Protection Act and cannot be shared. The primary care data can be requested via application to the Clinical Practice Research Datalink, with secondary care data and mortality data through linkage upon application. Information is available from https://www.cprd.com/research-applications.
